ATP gatekeeper of Plasmodium protein kinase may provide the opportunity to develop selective antimalarial drugs with multiple targets by Fauze Mahmud et al.
ATP gatekeeper of Plasmodium protein kinase may provide the opportunity to
develop selective antimalarial drugs with multiple targets
ABSTRACT
Malaria is one of the most devastating infectious diseases that caused millions of clinical cases
annually despite decades of prevention efforts. Recent cases of Plasmodium falciparum
resistance against the only remaining class of effective antimalarial (artemisinin) in South East
Asia may soon pose a significant threat. Hence, the identification of new antimalarial
compounds with a novel mode of action is necessary to curb this problem. Protein kinase has
been implicated as a valid target for drug development in diseases such as cancer and diabetes
in humans. A similar approach is now recognized for the treatment of protozoan-related
disease including malaria. Few Plasmodium protein kinases that are not only crucial for their
survival but also have unique structural features have been identified as a potential target for
drug development. In this review, studies on antimalarial drug development exploiting the size
of Plasmodium protein kinase ATP gatekeeper over the past 15 years are mainly discussed. The
ATP-binding site of Plasmodium protein kinases such as Pf CDPK1, Pf CDPK4, Pf PKG, Pf PK7,
and Pf PI4K showed great potential for selective and multi-target inhibitions owing to their
smaller or unique ATP-gatekeeper amino acid subunits compared to that of human protein
kinase. Hence it is a feasible solution to identify a new class of active antimalarial agents with a
novel mode of action and longer clinical life-span.
